Bank of Montreal Can acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 35,586 shares of the company's stock, valued at approximately $415,000.
A number of other hedge funds have also bought and sold shares of the business. ARK Investment Management LLC lifted its position in shares of Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock valued at $146,174,000 after acquiring an additional 280,946 shares during the period. Vanguard Group Inc. raised its stake in Intellia Therapeutics by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock valued at $118,816,000 after purchasing an additional 562,249 shares in the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in Intellia Therapeutics during the fourth quarter worth about $43,177,000. Geode Capital Management LLC grew its stake in Intellia Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock worth $27,865,000 after buying an additional 45,930 shares in the last quarter. Finally, Contrarius Group Holdings Ltd acquired a new stake in Intellia Therapeutics during the fourth quarter worth about $11,798,000. 88.77% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
NTLA has been the subject of a number of recent analyst reports. Wells Fargo & Company cut their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Chardan Capital reduced their target price on Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Oppenheimer lowered their price target on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a report on Monday, January 13th. Barclays reduced their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, The Goldman Sachs Group reissued a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $36.68.
Read Our Latest Report on Intellia Therapeutics
Intellia Therapeutics Stock Performance
NASDAQ:NTLA opened at $8.31 on Wednesday. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The company has a 50 day simple moving average of $8.83 and a two-hundred day simple moving average of $12.01. The company has a market capitalization of $860.23 million, a PE ratio of -1.53 and a beta of 2.23.
Intellia Therapeutics Company Profile
(
Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Stories
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
